MARKET

XENT

XENT

Intersect ENT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.51
+0.54
+3.38%
Opening 11:33 06/24 EDT
OPEN
17.16
PREV CLOSE
15.97
HIGH
17.48
LOW
16.51
VOLUME
99.27K
TURNOVER
--
52 WEEK HIGH
26.98
52 WEEK LOW
11.66
MARKET CAP
547.15M
P/E (TTM)
-7.2336
1D
5D
1M
3M
1Y
5Y
Skepticism over AmeriSource acquisition speculation, GSK upgraded following investor update, and more in analyst action
LeoPatrizi/iStock via Getty Images AmerisourceBergen buying Parexel is unlikely AmerisourceBergen (ABC) potentially acquiring contract research organization Parexel -- as has been suggested in media reports -- is highly unlikely, according
Seekingalpha · 1h ago
SVB Leerink Upgrades Intersect ENT to Outperform From Market Perform, Adjusts Price Target to $23 From $21
MT Newswires · 7h ago
Estimating The Intrinsic Value Of Intersect ENT, Inc. (NASDAQ:XENT)
How far off is Intersect ENT, Inc. ( NASDAQ:XENT ) from its intrinsic value? Using the most recent financial data...
Simply Wall St. · 06/08 14:32
Intersect ENT Insights: Return On Capital Employed
In Q1, Intersect ENT (NASDAQ:XENT) posted sales of $24.33 million. Earnings were up 7.66%, but Intersect ENT still reported an overall loss of $18.57 million. In Q4, Intersect ENT brought in $28.23 million in sales but lost $17.25 million in earnings.
Benzinga · 06/07 14:01
BRIEF-Intersect Ent Inc - Effective June 4, Has Eliminated Chief Operating Officer Position
reuters.com · 06/07 13:09
Intersect ENT receives CE Mark approval for PROPEL Contour sinus implant
Intersect ENT (XENT) has received CE Mark approval for the company’s PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union.PROPEL Contour is specifically designed to maintain
Seekingalpha · 05/20 12:01
Intersect ENT Receives CE Mark Approval For PROPEL Contour For Patients With Chronic Rhinosinusitis Following Frontal Sinus Surgery
Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical
Benzinga · 05/20 11:48
Piper Sandler On Intersect ENT Following PROPEL, PROPEL Mini CE Mark Suspensions Being Lifted: Does Not Expect Any Material Impact On Co.'s Financials For Q2, 'we see the company as well-positioned to deliver against this international target'
Piper Sandler maintains a Neutral rating on Intersect ENT
Benzinga · 05/18 17:57
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XENT. Analyze the recent business situations of Intersect ENT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XENT stock price target is 23.00 with a high estimate of 32.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 186
Institutional Holdings: 40.56M
% Owned: 122.37%
Shares Outstanding: 33.14M
TypeInstitutionsShares
Increased
33
2.60M
New
13
594.60K
Decreased
39
2.32M
Sold Out
15
488.54K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.54%
Healthcare Equipment & Supplies
+0.28%
Key Executives
Non-Executive Chairman/Independent Director
Kieran Gallahue
President/Chief Executive Officer/Director
Thomas West
Chief Financial Officer/Executive Vice President
Richard Meier
Chief Human Resource Officer
Reyna Fernandez
Executive Vice President/General Counsel/Secretary
Patrick Broderick
Vice President/Director of Sales
Mark Alley
Independent Director
Neil Hattangadi
Independent Director
Teresa Kline
Independent Director
Cynthia Lucchese
Independent Director
Dana Mead
Independent Director
Elisabeth Sandoval-Little
No Data
About XENT
Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Webull offers kinds of Intersect ENT Inc stock information, including NASDAQ:XENT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XENT stock methods without spending real money on the virtual paper trading platform.